A scrap of data on Amgen’s obesity drug candidate wipes out $12 billion in market value

Taking stock of the drug industry, from the lab to the medicine chest

November 13, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Sarah Silbiger/Getty Images STAT+ | FDA is still struggling with a lack of inspectors, but doesn't have a plan, watchdog finds A key reason positions haven't been filled is that they require travel that ranges from 25% to 75% of the time. By Ed Silverman STAT+ | A scrap of data on Amgen's obesity drug candidate wipes out $12 billion in market value The company's stock fell 7% based on a single analyst note about unverified data on its lead obesity candidate. By Elaine Chen STAT+ | Buoyed by billion-dollar deals, its stock is up 50% this year. How did Boston Scientific get its mojo back? During chief executive Mike Mahoney's 12-year tenure, Boston Scientific has completed more than 40 acquisitions. By Jon Chesto — Boston Globe Adobe STAT+ | RNA startup Orna Therapeutics cuts more jobs Orna was part of a buzzy cohort of companies established in the wake of the Covid pandemic to create new, more durable types of RNA-based medicines. By Allison DeAngelis

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser